AI Summary & Key Takeaways
AI InsightBut the effectiveness of HDC for this group of patients and optimal dosing of drugs need further investigation
📌 3 Key Takeaways
Abstract
Patients with relapsed or refractory germ cell tumour have a poor prognosis. High-dose chemotherapy (HDC) with peripheral blood stem cell (PBSC) rescue has shown a curative potential in this group of patients. in this trial, the efficacy and toxicity of high-dose chemotherapy with peripheral blood stem cell transplantation was evaluated following induction with VIP regimen. Seven patients with relapsed or refractory germ cell cancer were treated with high-dose chemotherapy including ifosfamide 10 gr/m2), carboplatin (1gr/m2) and etoposide (1gr/m ) following induction therapy with VIP regimen (vinblastine, ifosfamide, cisplatin) between 1994 and 1999. The second course of HDC was given to the patients who achieved PR after the first HDC regimen. Two of 7 patients achieved complete response (CR), 4 achieved partial response (PR) and 1 had stable disease (SD) after the first course of HDC. Although 3 of 4 patients with PR received the second course of HDC, none of them achieved CR. At present, 3 of 7 patients (2 with CR and 1 with PR) are still alive, four patients died from progressive disease. The re was no transplant-related death. High-dose chemotherapy with peripheral blood stem cell transplantation following conventional dose induction therapy is well-tolerated and may improve the outcome in patients with refractory or relapsed germ cell tumor. But the effectiveness of HDC for this group of patients and optimal dosing of drugs need further investigation
Özet
High-dose chemotherapy with non-cryopreserved autologous peripheral stem cell transplantation in refractory/relapsed testicular carcinoma: Single center results